Twist Bioscience Stock Forecast, Price & News

-3.53 (-3.07 %)
(As of 07/27/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume526,090 shs
Average Volume790,122 shs
Market Capitalization$5.45 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TWST News and Ratings via Email

Sign-up to receive the latest news and ratings for Twist Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Twist Bioscience logo

About Twist Bioscience

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.55 out of 5 stars

Medical Sector

768th out of 2,218 stocks

Biological Products, Except Diagnostic Industry

111th out of 213 stocks

Analyst Opinion: 2.2Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Twist Bioscience (NASDAQ:TWST) Frequently Asked Questions

Is Twist Bioscience a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Twist Bioscience stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TWST, but not buy additional shares or sell existing shares.
View analyst ratings for Twist Bioscience
or view top-rated stocks.

What stocks does MarketBeat like better than Twist Bioscience?

Wall Street analysts have given Twist Bioscience a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Twist Bioscience wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Twist Bioscience's next earnings date?

Twist Bioscience is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Twist Bioscience

How can I listen to Twist Bioscience's earnings call?

Twist Bioscience will be holding an earnings conference call on Friday, August 6th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "3485949".

How were Twist Bioscience's earnings last quarter?

Twist Bioscience Co. (NASDAQ:TWST) released its quarterly earnings data on Thursday, May, 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.76) by $0.02. The company had revenue of $31.20 million for the quarter, compared to the consensus estimate of $28.18 million. Twist Bioscience had a negative trailing twelve-month return on equity of 25.47% and a negative net margin of 109.15%. The business's revenue was up 61.7% on a year-over-year basis. During the same quarter last year, the company posted ($0.85) earnings per share.
View Twist Bioscience's earnings history

How has Twist Bioscience's stock been impacted by COVID-19?

Twist Bioscience's stock was trading at $28.20 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TWST stock has increased by 295.3% and is now trading at $111.47.
View which stocks have been most impacted by COVID-19

What guidance has Twist Bioscience issued on next quarter's earnings?

Twist Bioscience updated its FY 2021 earnings guidance on Thursday, May, 27th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $121 million-$129 million, compared to the consensus revenue estimate of $120.21 million.

What price target have analysts set for TWST?

6 brokers have issued 1-year price targets for Twist Bioscience's stock. Their forecasts range from $100.00 to $200.00. On average, they anticipate Twist Bioscience's share price to reach $132.00 in the next year. This suggests a possible upside of 18.4% from the stock's current price.
View analysts' price targets for Twist Bioscience
or view top-rated stocks among Wall Street analysts.

Who are Twist Bioscience's key executives?

Twist Bioscience's management team includes the following people:
  • Dr. Emily Marine Leproust, Co-Founder, Chairman, Pres & CEO (Age 48, Pay $976.51k)
  • Mr. James M. Thorburn, Chief Financial Officer (Age 65, Pay $715.56k)
  • Mr. Patrick Weiss, Chief Operating Officer (Age 50, Pay $780.01k)
  • Dr. William Charles Banyai, Sr. VP of Advanced Devel., GM of Data Storage & Director (Age 66, Pay $591.56k)
  • Dr. Patrick John Finn, Chief Commercial Officer (Age 49, Pay $693.68k)
  • Mr. Siyuan Chen, Chief Technology Officer
  • Dr. Aaron K. Sato, Chief Scientific Officer & Chief Scientific Officer of BioPharma
  • Ms. Paula Green, Sr. VP of HR (Age 53)
  • Mr. Martin Kunz, Sr. VP of Bus. Technologies (Age 50)
  • Ms. Erin Smith, Sr. VP of Gov. Affairs & Public Policy

What is Emily Leproust's approval rating as Twist Bioscience's CEO?

44 employees have rated Twist Bioscience CEO Emily Leproust on Emily Leproust has an approval rating of 83% among Twist Bioscience's employees.

Who are some of Twist Bioscience's key competitors?

What other stocks do shareholders of Twist Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), DocuSign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), (JD), Tesla (TSLA) and Twilio (TWLO).

When did Twist Bioscience IPO?

(TWST) raised $75 million in an IPO on Wednesday, October 31st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Cowen acted as the underwriters for the IPO and Allen & Company and Baird were co-managers.

What is Twist Bioscience's stock symbol?

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

How do I buy shares of Twist Bioscience?

Shares of TWST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Twist Bioscience's stock price today?

One share of TWST stock can currently be purchased for approximately $111.47.

How much money does Twist Bioscience make?

Twist Bioscience has a market capitalization of $5.45 billion and generates $90.10 million in revenue each year. The company earns $-139,930,000.00 in net income (profit) each year or ($3.00) on an earnings per share basis.

How many employees does Twist Bioscience have?

Twist Bioscience employs 525 workers across the globe.

What is Twist Bioscience's official website?

The official website for Twist Bioscience is

Where are Twist Bioscience's headquarters?

Twist Bioscience is headquartered at 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080.

How can I contact Twist Bioscience?

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 800-719-0671 or via email at [email protected]

This page was last updated on 7/27/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.